Published in J Crohns Colitis on January 15, 2012
Adverse effects of smoking in ulcerative colitis. J Crohns Colitis (2012) 1.06
Microbiome-Epigenome Interactions and the Environmental Origins of Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr (2016) 0.78
Reply to Dr Kountouras et al.'s letter. J Crohns Colitis (2012) 0.75
Reactive oxygen species in organ-specific autoimmunity. Auto Immun Highlights (2016) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 3.97
Management of Crohn's disease in adults. Am J Gastroenterol (2009) 3.94
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol (2007) 2.77
Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc (2007) 2.76
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc (2006) 2.73
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Prospective comparison of patient experience with colon imaging tests. Am J Med (2006) 2.42
Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. Gastrointest Endosc (2008) 2.42
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.36
Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis (2010) 2.22
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology (2009) 2.09
Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol (2006) 2.03
Computerized detection of colonic polyps at CT colonography on the basis of volumetric features: pilot study. Radiology (2002) 1.93
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol (2003) 1.86
AGA technical review on perianal Crohn's disease. Gastroenterology (2003) 1.80
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol (2006) 1.79
Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol (2006) 1.76
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology (2003) 1.70
Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut (2011) 1.70
Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol (2005) 1.64
Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest (2008) 1.64
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol (2002) 1.63
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57
African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol (2010) 1.52
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging (2011) 1.46
Computer-aided diagnosis scheme for detection of polyps at CT colonography. Radiographics (2002) 1.45
Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology (2005) 1.44
Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm Bowel Dis (2003) 1.42
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol (2011) 1.41
Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis (2007) 1.40
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol (2007) 1.39
Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest (2013) 1.38
Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am J Gastroenterol (2003) 1.37
Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis (2013) 1.33
American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology (2013) 1.32
Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol (2008) 1.30
Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol (2010) 1.30
The 'upside' of travelers' diarrhea: a personal case report. Nat Clin Pract Gastroenterol Hepatol (2005) 1.28
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis (2009) 1.25
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol (2008) 1.21
miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm Bowel Dis (2011) 1.20
Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med (2012) 1.20
Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol (2013) 1.17
Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol (2005) 1.15
Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology (2012) 1.15
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.14
Benign solitary cecal ulcer: a case report and review of the literature. Dig Dis Sci (2003) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis (2013) 1.13
Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol (2005) 1.10
Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we? Inflamm Bowel Dis (2011) 1.09
Tyler, Faecalibacterium and biodiversity. Nat Clin Pract Gastroenterol Hepatol (2009) 1.08
Infectious proctitis: when to suspect it is not inflammatory bowel disease. Dig Dis Sci (2011) 1.05
Diverticulitis in the young patient--is it different ? World J Gastroenterol (2006) 1.03
Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis (2013) 1.02
Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis (2014) 1.01
Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis (2013) 1.00
Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis (2009) 0.98
Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis (2013) 0.98
I've sold my sport-utility vehicle. Nat Clin Pract Gastroenterol Hepatol (2005) 0.96
Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord (2004) 0.96
Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease. Ann Behav Med (2007) 0.95
The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm (2008) 0.94
Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol (2003) 0.94
Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis (2016) 0.93
p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci (2007) 0.93
When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Dis (2010) 0.93
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol (2010) 0.93
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis (2010) 0.92
The changing face of colorectal cancer in inflammatory bowel disease: progress at last! Gastroenterology (2006) 0.92
Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am J Gastroenterol (2006) 0.92
Association between colorectal cancer and urologic cancers. Arch Intern Med (2008) 0.91
Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis (2010) 0.90
Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2007) 0.90
Role of colonoscopy in patients with persistent acute diverticulitis. World J Gastroenterol (2008) 0.89
Comparison of routine and unprepped CT colonography augmented by low fiber diet and stool tagging: a pilot study. Abdom Imaging (2006) 0.89
Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol (2006) 0.89